Investigate the effect of Crocin in Multiple Sclerosis patients

Investigate the effect of Crocin on Cognitive impairment, mental health,Oxidative Stress and inflammatory factors in Multiple Sclerosis patients

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220221054087N1

Enrollment

Registered

2022-03-09

Start date

2022-04-08

Completion date

Unknown

Last updated

2022-04-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis. Multiple sclerosis

Interventions

Intervention 1: Intervention group: In this group of patients (n=25) will be requested to take two crocin tablets daily for 8 weeks (each tablet contain 15 mg crocin). The crocin tablets will be produ

Eligibility

Sex/Gender

All

Age

18 Years to 55 Years

Inclusion criteria

Inclusion criteria: Diagnosis of Multiple Sclerosis based on McDonald's criteria Age between 18 to 55 years Testable Measurable Cognitive impairment (MACFIMS) attributed to Multiple Sclerosis Testable Measurable mental health impairment including anxiety and depression (Beck) attributed to Multiple Sclerosis

Exclusion criteria

Exclusion criteria: Pregnancy Breast feeding History of Diabetes, heart failure, renal failure ,hepatic failure and psychological disorder History of substance addiction Sensitivity to crocin products Clinical relapse of Multiple Sclerosis with in 30 days of screening Changes in the treatment of Multiple Sclerosis within 30 days of screening Existence of any underlying factor and disease that causes dementia and cognitive impairment

Design outcomes

Primary

Measure	Time frame
Cognitive Disorder Score in MacFims Questionnaire. Timepoint: Perform MacFims test at the beginning of the study and 8 weeks after of the study. Method of measurement: MacFims Questionnaire.;Accompanying depression score. Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: Beck's Depression Inventory.;Accompanying anxiety score. Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: Beck's anxiety Inventory.	—

Measure

Time frame

Cognitive Disorder Score in MacFims Questionnaire. Timepoint: Perform MacFims test at the beginning of the study and 8 weeks after of the study. Method of measurement: MacFims Questionnaire.;Accompanying depression score. Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: Beck's Depression Inventory.;Accompanying anxiety score. Timepoint: At the beginning of the study and 8 weeks later. Method of measurement: Beck's anxiety Inventory.

—

Secondary

Measure	Time frame
Total antioxidant. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Spectrophotometry.;Total glutathione. Timepoint: At the beginning of the study and after 8weeks of intervention. Method of measurement: Spectrophotometry.;Malondialdehyde. Timepoint: At the beginning of the study and after 8weeks of intervention. Method of measurement: Spectrophotometry.;Hs-CRP. Timepoint: At the beginning of the study and after 8weeks of intervention. Method of measurement: Elisa kit.	—

Measure

Time frame

Total antioxidant. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: Spectrophotometry.;Total glutathione. Timepoint: At the beginning of the study and after 8weeks of intervention. Method of measurement: Spectrophotometry.;Malondialdehyde. Timepoint: At the beginning of the study and after 8weeks of intervention. Method of measurement: Spectrophotometry.;Hs-CRP. Timepoint: At the beginning of the study and after 8weeks of intervention. Method of measurement: Elisa kit.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBahador Rezapoor Kafteroodi

Kashan University of Medical Sciences

Bahador.rezapoor@gmail.com+98 31 5554 0026

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026